1. Guttman-Yassky, Emma, Bissonnette, Robert, Ungar, Benjamin, Yancopoulos, George D, D Hamilton, Jennifer D. 2018. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. In The Journal of allergy and clinical immunology, 143, 155-172. doi:10.1016/j.jaci.2018.08.022. https://pubmed.ncbi.nlm.nih.gov/30194992/
2. Tian, Peng, Ou, Huashuang, Wu, Fan, Dang, Hua, Zou, Hua. 2018. Interleukin-4-induced posttranscriptional gene regulation of CCL26 by the RNA-binding protein HuR in primary human nasal polyp-derived epithelial cells. In International forum of allergy & rhinology, 9, 311-321. doi:10.1002/alr.22250. https://pubmed.ncbi.nlm.nih.gov/30472791/
3. Sun, Aitao, Li, YunHua, Jiang, Xiaodong. 2022. CCL26 silence represses colon cancer by inhibiting the EMT signaling pathway. In Tissue & cell, 79, 101937. doi:10.1016/j.tice.2022.101937. https://pubmed.ncbi.nlm.nih.gov/36156375/
4. Marella, Sahiti, Sharma, Ankit, Ganesan, Varsha, Chehade, Mirna, Hogan, Simon P. 2023. IL-13-induced STAT3-dependent signaling networks regulate esophageal epithelial proliferation in eosinophilic esophagitis. In The Journal of allergy and clinical immunology, 152, 1550-1568. doi:10.1016/j.jaci.2023.07.021. https://pubmed.ncbi.nlm.nih.gov/37652141/
5. Li, Zhipeng, Zeng, Ming, Deng, Yanhan, Lee, Stella E, Wenzel, Sally E. 2019. 15-Lipoxygenase 1 in nasal polyps promotes CCL26/eotaxin 3 expression through extracellular signal-regulated kinase activation. In The Journal of allergy and clinical immunology, 144, 1228-1241.e9. doi:10.1016/j.jaci.2019.06.037. https://pubmed.ncbi.nlm.nih.gov/31301373/
6. Guttman-Yassky, Emma, Kabashima, Kenji, Staumont-Salle, Delphine, Blauvelt, Andrew, Reich, Kristian. 2024. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. In Allergy, 79, 1560-1572. doi:10.1111/all.16108. https://pubmed.ncbi.nlm.nih.gov/38563683/
7. Hamilton, Jennifer D, Suárez-Fariñas, Mayte, Dhingra, Nikhil, Pirozzi, Gianluca, Guttman-Yassky, Emma. . Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. In The Journal of allergy and clinical immunology, 134, 1293-1300. doi:10.1016/j.jaci.2014.10.013. https://pubmed.ncbi.nlm.nih.gov/25482871/
智鼠故事 
